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Introduction {#sec005}
============

Atrial fibrillation (AF) is the most common type of sustained arrhythmia. Patients with certain risk factors have a significantly increased risk of stroke \[[@pone.0212278.ref001]\]. Prevalence of AF increases with age and reaches almost 9% in patients aged 80--89 \[[@pone.0212278.ref002]\]. It is important to note that cardiac thromboembolism accounts for 15 to 20% of all strokes \[[@pone.0212278.ref003]\].

The risk of thromboembolism in patients with AF is commonly assessed using clinical variables such as congestive heart failure (CHF), hypertension, age, diabetes mellitus, and prior stroke or transient ischemic attack (TIA) in the initial CHADS~2~ risk score, as well as in the currently widely recommended CHA~2~DS~2~-VASc risk score, which includes additional variables (vascular disease and sex) \[[@pone.0212278.ref004],[@pone.0212278.ref005]\]. However, the performance of this score is limited when measured by C statistic of 0.606 \[95% confidence interval (CI): 0.513--0.699\], which is only slightly better than the CHADS~2~-Score (0.561 \[95% CI: 0.450--0.672\]) \[[@pone.0212278.ref005]\].

Current European Society of Cardiology guidelines for the management of AF recommend anticoagulation when CHA~2~DS~2~-VASc score is 2 or higher in men and 3 or higher in women, and refrain from anticoagulation in men with a score of 0 and women with a score of 1 only due to female gender. With a CHA~2~DS~2~-VASc score of 1 in men and 2 in women, consideration of anticoagulation is recommended depending on expected stroke rate, bleeding risk and patient preference \[[@pone.0212278.ref004]\].

Cardiac troponin elevations are associated with underlying heart disease and adverse events in patients with acute coronary syndrome (ACS) \[[@pone.0212278.ref006]\], stable coronary artery disease (CAD) \[[@pone.0212278.ref007]\], chronic heart failure \[[@pone.0212278.ref008]\], and in community-based populations \[[@pone.0212278.ref009]\]. It has been demonstrated that elevated levels of cardiac troponin are highly prevalent among patients with acute ischemic stroke and are associated with higher mortality \[[@pone.0212278.ref010],[@pone.0212278.ref011]\]. Suggested pathophysiologic mechanisms include neurally mediated autonomic dysregulation and cardiac injury secondary to sympathoadrenal activation \[[@pone.0212278.ref012]\].

The prognostic value of biomarkers in patients with AF regarding stroke risk prediction has not been established conclusively. Current evidence for association of elevated cardiac troponin levels with higher stroke risk in patients with AF is based on secondary analyses of randomized controlled trials (RCT)--such as the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial \[[@pone.0212278.ref013]\] and the Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) trial \[[@pone.0212278.ref014]\]. Recently, novel risk scores for patients with AF using biomarkers have been derived from RCT populations \[[@pone.0212278.ref015]--[@pone.0212278.ref017]\]. In the setting of an emergency department, we have shown, that elevated cardiac troponin levels are associated with higher mortality in patients with AF \[[@pone.0212278.ref018]\].

We aimed to assess real-world data by investigating the association of high-sensitivity cardiac troponin T (hsTnT) levels with stroke risk in an unselected population of patients presenting to an emergency department with AF, especially in relation to clinical risk factors and the CHA~2~DS~2~-VASc risk score.

Methods {#sec006}
=======

Study population and design {#sec007}
---------------------------

All patients admitted to the emergency department of the Department of Cardiology of the Heidelberg University Hospital from June 2009 to May 2013 with AF in the admission electrocardiogram (ECG) or history of AF were included. Patients presenting from 11th November 2011 to 9th December 2011 could not be included, since electronic medical record software was unavailable for this period. There were 22 993 visits to our emergency department, where hsTnT is routinely measured upon admission in all patients. There were 5120 visits of patients with AF (4708 patients had AF in the admission ECG and 412 patients had no AF in the admission ECG but a history of AF). Of these, 2083 were removed due to repeat visits, 93 were removed since detailed evaluation showed incorrect diagnosis of AF, and 46 patients were removed, since hsTnT upon admission was unavailable. The final study population consisted of 2898 patients ([Fig 1](#pone.0212278.g001){ref-type="fig"}). This retrospective observational study had no influence on patient treatment. All treatments were provided at the discretion of the treating physicians.

![Diagram of patient inclusion.\
\* Medical record software not in use from 11 November 2011 to 9 December 2011 AF denotes atrial fibrillation, hsTnT high-sensitivity troponin T. (Reproduced with permission from Oxford University Press \[[@pone.0212278.ref018]\]).](pone.0212278.g001){#pone.0212278.g001}

This study was approved by the Ethics Committee of the Medical Faculty of Heidelberg, requiring no informed consent for this retrospective analysis of patients from our own institution, using data from routine care. This study was conducted according to ethical principles stated in the Declaration of Helsinki (2008). Patient identifiable data was pseudonymized to ensure data confidentiality and was not passed on to third parties. This study is registered at ClinicalTrials.gov (NCT02542189).

Follow-up was performed by review of in- and outpatient visits to our clinic via hospital information system and review of results of routine medical aftercare, which is performed via patient phone calls, postal queries with standardized questionnaires, contact with primary care physicians and letters to registration offices. Patients without follow-up on ischemic stroke were not included in the survival analysis regarding this endpoint. All reported events were adjudicated by a physician after a follow-up of at least 1 month up to 60 months. Patients with hemorrhagic stroke were excluded.

HsTnT was measured on Cobas E411 (Roche Diagnostics Ltd., Rotkreuz, Switzerland). Limit of blank (3 ng/L) and limit of detection (5 ng/L) were determined in accordance with CLSI guideline EP17-A. Details on assay performance and analytical characteristics have previously been reported \[[@pone.0212278.ref019]\]. Normal reference values were established in a multicenter reference study and the 99th percentile value was determined at 14 ng/L \[[@pone.0212278.ref019]\]. Assay performance was not re-assessed in our central laboratory. None of the lots used in our central laboratory were affected by a lot-to-lot variation issue that has been reported for hsTnT \[[@pone.0212278.ref020]\]. The diagnosis of acute myocardial infarction was based on the third universal definition of myocardial infarction, requiring a rise and/or fall of hsTnT with at least one value above the 99th percentile (14 ng/L) \[[@pone.0212278.ref021]\].

Baseline characteristics are reported for the overall group as well as for two subgroups based on hsTnT levels: hsTnT at or below the 99th percentile and hsTnT above the 99th percentile (elevated hsTnT).

CHA~2~DS~2~-VASc score {#sec008}
----------------------

CHA~2~DS~2~-VASc score was calculated for all patients by adding two points for age ≥ 75 years and prior stroke or transient ischemic attack, respectively; as well as one point for congestive heart failure (left ventricular ejection fraction \< 45% or main admission diagnosis of heart failure), hypertension, age between 65--74 years, diabetes mellitus, prior myocardial infarction or peripheral artery disease, and female gender, respectively \[[@pone.0212278.ref005]\].

Statistical analysis {#sec009}
--------------------

Data are presented as means (standard deviations), medians (25th, 75th percentiles), Kaplan-Meier estimates, counts or percentages. Continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test. Groups were compared using chi-squared test or Fisher's exact test for categorical variables, and unpaired Student's t-test or Wilcoxon rank-sum test for continuous variables. Kaplan-Meier analysis was performed and groups were compared with the log-rank test. A multivariate Cox proportional hazards regression was performed to determine predictors for stroke. The proportional hazards assumption was tested using the Grambsch and Therneau method \[[@pone.0212278.ref022]\]. Time-dependent receiver-operating-characteristic (ROC) curves from censored survival data using the Kaplan-Meier method were estimated and the area under the ROC curves (AUC) was calculated \[[@pone.0212278.ref023]\]. The 95% confidence interval (CI) of AUC was calculated according to Hanley and McNeil \[[@pone.0212278.ref024]\]. To assess the added value of hsTnT regarding stroke prediction, measures for evaluating its incremental value, integrated discrimination improvement (IDI) and continuous net reclassification improvement (NRI) were calculated using censored time-to-event data \[[@pone.0212278.ref025]\]. A two tailed P-value of \<0.05 was considered to indicate statistical significance. All statistical analyses were performed using R 3.3.3 (The R Foundation for Statistical Computing, Vienna, Austria).

Results {#sec010}
=======

Baseline characteristics {#sec011}
------------------------

Baseline characteristics are reported for the overall group as well as for both subgroups based on hsTnT level: hsTnT at or below the 99th percentile and hsTnT above the 99th percentile (elevated hsTnT) ([Table 1](#pone.0212278.t001){ref-type="table"}). The groups differed significantly with respect to the baseline variables. The majority of patients were male (58.8%). Median age increased with higher troponin-values with a median of 78 years in patients with elevated hsTnT. Cardiovascular risk factors were more prevalent in patients with hsTnT above the 99th percentile.

10.1371/journal.pone.0212278.t001

###### Baseline characteristics.

![](pone.0212278.t001){#pone.0212278.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                        All Patients\      hsTnT ≤ 14 ng/L\   hsTnT \> 14 ng/L\   P-Value
                                                                                                        (n = 2898)         (n = 1267)         (n = 1631)          
  ----------------------------------------------------------------------------------------------------- ------------------ ------------------ ------------------- ----------
  Age (years)                                                                                           74 \[66--81\]      69 \[59--75\]      78 \[71--84\]       \< 0.001

  Male sex                                                                                              1704/2898 (58.8)   699/1267 (55.2)    1005/1631 (61.6)    \<0.001

  Diabetes mellitus                                                                                     785/2887 (27.2)    222/1263 (17.6)    563/1624 (34.7)     \< 0.001

  Arterial hypertension                                                                                 2368/2884 (82.1)   952/1263 (75.4)    1416/1621 (87.4)    \< 0.001

  Prior stroke or transient ischemic attack                                                             298/2887 (10.3)    89/1265 (7.0)      209/1622 (12.9)     \< 0.001

  Peripheral artery disease                                                                             237/2886 (8.2)     49/1264 (3.9)      188/1622 (11.6)     \< 0.001

  Coronary artery disease                                                                               1322/2880 (45.9)   420/1262 (33.3)    902/1618 (55.7)     \< 0.001

  Prior myocardial infarction                                                                           501/2885 (17.4)    116/1264 (9.2)     385/1621 (23.8)     \< 0.001

  Prior percutaneous coronary intervention                                                              604/2878 (21.0)    189/1264 (15.0)    415/1615 (25.7)     \< 0.001

  Prior coronary artery bypass surgery                                                                  277/2886 (9.6)     60/1264 (4.7)      217/1622 (13.4)     \< 0.001

  Reduced ejection fraction (moderately or severely, \< 45%)                                            601/1787 (33.6)    115/669 (17.2)     486/1118 (43.5)     \< 0.001

  Valvular atrial fibrillation                                                                          186/2475 (7.5)     38/1102 (3.4)      148/1373 (10.8)     \< 0.001

  Atrial fibrillation in admission electrocardiogram (ECG)                                              2628/2891 (90.9)   1110/1265 (87.7)   1518/1626 (93.4)    \< 0.001

  Estimated glomerular filtration rate (eGFR)[\*](#t001fn002){ref-type="table-fn"} (mL/min/1.73 m^2^)   71 \[51--88\]      82 \[67--97\]      59 \[41--79\]       \< 0.001

  Severely impaired renal function (eGFR \< 30 mL/min/1.73 m^2^)                                        208/2888 (7.2)     8/1260 (0.6)       200/1628 (12.3)     \< 0.001

  Liver cirrhosis                                                                                       25/2884 (0.9)      9/1265 (0.7)       16/1619 (1.0)       0.553

  Aspartate transaminase (AST) (IU/L)                                                                   27 \[20--37\]      25 \[20--33\]      28 \[21--42\]       \< 0.001

  Aspartate transaminase (AST) \> 2 x upper limit of normal (ULN)                                       138/2863 (4.8)     32/1254 (2.6)      106/1609 (6.6)      \< 0.001

  Prior major bleeding                                                                                  146/2875 (5.1)     36/1265 (2.8)      110/1610 (6.8)      \< 0.001
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are median \[25th, 75th percentiles\] or number of patients (%)

\* By Modification of Diet in Renal Disease (MDRD) equation

The majority of patients had AF in the admission ECG (90.9%) and AF was the most frequent main admission diagnosis (42.7%). The frequencies of other admission diagnoses are listed in [Table 2](#pone.0212278.t002){ref-type="table"}. At discharge, 6.7% of all patients (3.6% of patients with hsTnT at or below the 99th percentile and 9.3% of patients with elevated hsTnT, p \< 0.001) were treated with triple therapy (oral anticoagulation, aspirin and a P2Y~12~ inhibitor).

10.1371/journal.pone.0212278.t002

###### Main admission diagnoses.

![](pone.0212278.t002){#pone.0212278.t002g}

  ---------------------------------------------------------------------------------------------------------------------
                                                   All Patients\      hsTnT ≤ 14 ng/L\   hsTnT \> 14 ng/L\   P-Value
                                                   (n = 2898)         (n = 1267)         (n = 1631)          
  ------------------------------------------------ ------------------ ------------------ ------------------- ----------
  Atrial fibrillation                              1236/2898 (42.7)   819/1267 (64.6)    417/1631 (25.6)     \< 0.001

  Heart failure                                    307/2898 (10.6)    60/1267 (4.7)      247/1631 (15.1)     \< 0.001

  Hypertensive emergency                           83/2898 (2.9)      45/1267 (3.6)      38/1631 (2.3)       0.065

  Infection                                        182/2898 (6.3)     32/1267 (2.5)      150/1631 (9.2)      \< 0.001

  Unstable angina                                  146/2898 (5.0)     58/1267 (4.6)      88/1631 (5.4)       0.361

  Non-ST-segment elevation myocardial infarction   203/2898 (7.0)     6/1267 (0.5)       197/1631 (12.1)     \< 0.001

  ST-segment elevation myocardial infarction       35/2898 (1.2)      3/1267 (0.2)       32/1631 (2.0)       \< 0.001

  Other diagnoses                                  706/2898 (24.4)    244/1267 (19.3)    462/1631 (28.3)     \< 0.001
  ---------------------------------------------------------------------------------------------------------------------

Data are number of patients (%)

CHA~2~DS~2~-VASc score was available in 99.0% of patients. The majority of patients included in this study had a CHA~2~DS~2~-VASc score of 2 or higher (83.4%). A total of 71.3% of patients with hsTnT at or below the 99th percentile and 92.8% of patients with hsTnT above the 99th percentile had a CHA~2~DS~2~-VASc score of 2 or higher ([Fig 2](#pone.0212278.g002){ref-type="fig"}).

![Distribution of CHA~2~DS~2~-VASc score in patients with atrial fibrillation for the subgroups of hsTnT under the 99th percentile (A. hsTnT ≤ 14 ng/L), and elevated hsTnT (B. hsTnT \> 14 ng/L).\
hsTnT = high-sensitivity troponin T.](pone.0212278.g002){#pone.0212278.g002}

Median follow-up duration for stroke was 710.0 days \[25th-- 75th percentiles: 289.5--1061.5 days\]. Follow-up information on vital status and stroke could be obtained in 94.3% and 76.7%, respectively. On admission, median hsTnT was 17.0 ng/L (25th percentile 9.0 ng/L, and 75th percentile 37.0 ng/L) and mean hsTnT was 67.8 ng/L.

Prognostic value of high-sensitivity cardiac troponin T {#sec012}
-------------------------------------------------------

In total, there were 60 cases of stroke. In the subgroup of patients with hsTnT at or below the 99th percentile there were 16 cases of stroke and in patients with elevated hsTnT there were 44 cases (Kaplan--Meier estimates for stroke at 1 year 0.9%, and 2.9%, respectively). Kaplan--Meier curves are shown in [Fig 3](#pone.0212278.g003){ref-type="fig"}. A log-rank test for the two hsTnT-subgroups was significant (P\<0.001).

![Kaplan-Meier curve for stroke in patients with atrial fibrillation: hsTnT under the 99th percentile (hsTnT ≤ 14 ng/L, blue), and elevated hsTnT (hsTnT \> 14 ng/L, red).\
hsTnT = high-sensitivity troponin T.](pone.0212278.g003){#pone.0212278.g003}

A multivariate Cox proportional hazards model was used to determine predictors for stroke in patients with AF. HsTnT, as well as all variables of the CHA~2~DS~2~-VASc score were included. Among these, elevated hsTnT levels, higher age, and prior stroke or transient ischemic attack were significantly associated with an increased risk of stroke in patients with AF. Adjusted hazard ratio for elevated hsTnT was 2.35 \[95% CI: 1.26--4.36\] (P = 0.007) ([Table 3](#pone.0212278.t003){ref-type="table"}).

10.1371/journal.pone.0212278.t003

###### Results of Cox proportional-hazards regression for predictors of stroke in patients with atrial fibrillation.

![](pone.0212278.t003){#pone.0212278.t003g}

  -------------------------------------------------------------------------------------------------------
                                                                  Adjusted Hazard Ratio\        P-Value
                                                                  \[95% Confidence Interval\]   
  --------------------------------------------------------------- ----------------------------- ---------
  Elevated high-sensitivity cardiac troponin T (\> 14 ng/L)       2.35 \[1.26--4.36\]           0.007

  Congestive heart failure[\*](#t003fn001){ref-type="table-fn"}   1.04 \[0.58--1.85\]           0.905

  Hypertension                                                    0.97 \[0.43--2.19\]           0.945

  Age ≥ 75 years (versus \< 65 years)                             3.35 \[1.12--10.02\]          0.031

  Age 65--74 years (versus \< 65 years)                           3.57 \[1.21--10.52\]          0.021

  Diabetes mellitus                                               1.47 \[0.86--2.51\]           0.161

  Prior stroke or transient ischemic attack                       2.06 \[1.06--4.00\]           0.032

  Prior myocardial infarction or peripheral artery disease        0.82 \[0.44--1.55\]           0.544

  Sex (female)                                                    1.19 \[0.69--2.05\]           0.529
  -------------------------------------------------------------------------------------------------------

\* Left ventricular ejection fraction \< 45% or main admission diagnosis of heart failure

The inclusion of hsTnT in the multivariable model for stroke prediction, which included all variables of CHA~2~DS~2~-VASc score, was associated with a significant improvement of its performance. The inclusion of elevated hsTnT resulted in an IDI 0.004 \[95% CI: 0.001--0.012\] (P = 0.027) and continuous NRI 0.244 \[95% CI: 0.061--0.385\] (P = 0.013) for 1-year stroke risk.

The diagnostic performance of hsTnT regarding stroke at 1 year was reflected by the AUC of 0.659 \[95% CI: 0.575--0.742\], as compared to 0.610 \[95% CI: 0.526--0.694\] for the CHA~2~DS~2~-VASc score (P = 0.250) ([Fig 4](#pone.0212278.g004){ref-type="fig"}). For the combination of hsTnT and CHA~2~DS~2~-VASc score, AUC was 0.580 \[95% CI: 0.560--0.601\].

![Receiver operating characteristic (ROC) curves for prediction of stroke by hsTnT (red) and CHA~2~DS~2~-VASc score (blue) in patients with atrial fibrillation (P = 0.250).\
AUC = area under the curve, hsTnT = high-sensitivity troponin T, 95% CI = 95% confidence interval.](pone.0212278.g004){#pone.0212278.g004}

Calculating time-dependent ROC curves for censored time-to-event data, the maximum value of the Youden's Index was determined at a cut-off value of hsTnT 19.23 ng/L (sensitivity 73.1%, specificity 60.5%, positive predictive value 3.4% and negative predictive value 99.1% at 1 year).

Elevated hsTnT levels were also significantly associated with an increased risk of stroke after exclusion of patients with MI (NSTEMI and STEMI) as main admission diagnosis (2660 patients after exclusion of MI). In this subgroup the adjusted HR for elevated hsTnT (\> 14 ng/ L) was 2.06 \[95% CI: 1.07--3.95\] (P = 0.030).

In a ROC-curve analysis regarding stroke after exclusion of MI patients, hsTnT had an AUC of 0.643 \[95% CI: 0.559--0.727\], the CHA~2~DS~2~-VASc score an AUC of 0.639 \[95% CI: 0.555--0.723\], and the combination of hsTnT and CHA~2~DS~2~-VASc score an AUC of 0.613 \[95% CI: 0.592--0.635\], showing results similar to those of the entire population. After exclusion of patients with MI, maximum value of the Youden's Index was calculated at the same cut-off value of hsTnT 19.23 ng/L (sensitivity 66.5%, specificity 64.7%, positive predictive value 3.0% and negative predictive value 99.0% at 1 year).

An overall consistency of the hazard was observed across relevant subgroups of patients. There were no significant interactions regarding important potential confounders, such as age, renal function, ejection fraction, CHA~2~DS~2~-VASc score, AF as main admission diagnosis or ACS at admission ([Fig 5](#pone.0212278.g005){ref-type="fig"}).

![Stroke risk in patients with atrial fibrillation and subgroups for elevated hsTnT (hsTnT \> 14 ng/L) compared to hsTnT under the 99th percentile (hsTnT ≤ 14 ng/L).\
ACS = acute coronary syndrome, AF = atrial fibrillation, GFR = glomerular filtration rate, hsTnT = high-sensitivity troponin T. \* By Modification of Diet in Renal Disease (MDRD) equation (mL/min/1.73 m^2^).](pone.0212278.g005){#pone.0212278.g005}

In the subgroup of female patients with CHA~2~DS~2~-VASc score 0, 1 and 2 and male patients with CHA~2~DS~2~-VASc score 0 and 1, there were only 2 stroke events--one of them in the group of elevated hsTnT, the other in the group of hsTnT at or below 99th percentile ([S1 Fig](#pone.0212278.s001){ref-type="supplementary-material"}).

Discussion {#sec013}
==========

The present study of consecutive patients with AF presenting to an emergency department shows that elevated hsTnT levels are significantly associated with higher risk of stroke. In the model including all CHA~2~DS~2~-VASc score variables, hsTnT remains independently associated higher stroke risk and provides added prognostic information independent of other major risk factors and clinical characteristics. The inclusion of hsTnT is associated with a significant improvement of the discriminatory power of a model consisting of the CHA~2~DS~2~-VASc score variables.

The underlying mechanisms of why elevated troponin levels help identify patients at risk for stroke are not fully understood, but likely to be numerous and not only related to acute myocardial ischemia. Possible explanations for troponin elevations in patients with AF include myocardial injury due to high ventricular rates in tachyarrhythmia, microvascular blood flow alterations and oxidative stress \[[@pone.0212278.ref026]\]. An association of elevated troponin levels with extensive atherosclerosis, carotid lesions, and increased left ventricular filling pressures has also been reported, which may mediate a higher risk for stroke.

The prognostic value of biomarkers in patients with AF regarding stroke risk prediction has been addressed in several previous studies. Secondary analyses of RCTs comparing the efficacy and safety of novel oral anticoagulants (NOACs) with warfarin provided evidence for association of elevated cardiac troponin levels with adverse outcomes in patients with AF, including increased stroke risk. In a substudy of ARISTOTLE trial, high-sensitivity troponin-I was significantly associated with stroke or systemic embolism with an adjusted HR of 1.98 \[95% CI: 1.42--2.78\] \[[@pone.0212278.ref027]\]. In another analysis of the ARISTOTLE trial, annual rates of stroke or systemic embolism were significantly higher in the highest high-sensitivity troponin T quartile compared with the lowest quartile (adjusted HR 1.94 \[95% CI: 1.35--2.78\]) \[[@pone.0212278.ref014]\].

Recently, biomarker-based risk scores for patients with AF have been introduced. The Age, Biomarkers, Clinical history (ABC) score was derived from a cohort of 14 701 patients from the ARISTOTLE trial \[[@pone.0212278.ref015]\]. In a subanalysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation--Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial, a multimarker risk score including cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and D-dimer levels was developed \[[@pone.0212278.ref016]\]. When added to the CHA~2~DS~2~-VASc score, the biomarker score based on the ENGAGE AF-TIMI 48 trial significantly enhanced prognostic accuracy by improving the C statistic from 0.586 \[95% CI: 0.565--0.607\] to 0.708 \[95% CI: 0.688--0.728\] (P \< 0.001) and reclassification with a net reclassification improvement of 59.4% (P \< 0.001).

The findings of the present study are novel and add information to available data for several reasons. First, data was collected from unselected patients presenting to an emergency department, including patients with clinical characteristics, many of which had been excluded in previous randomized controlled trials. Patients with valvular AF, severely impaired renal function, liver disease, previous major bleeding and triple therapy (simultaneous treatment with oral anticoagulation, aspirin and a P2Y~12~ inhibitor) were all included, therefore better reflecting the real world setting.

Second, we were able to investigate the prognostic role of hsTnT across a wide spectrum of cardiac comorbidities that may contribute to hsTnT elevation and could also explain the prognostic impact of hsTnT in AF. HsTnT was significantly associated with higher stroke risk independently of important risk factors and clinical characteristics. Furthermore, a subgroup analysis of the present study showed that the prognostic impact of elevated hsTnT in AF is consistent throughout relevant subgroups--no significant interactions were observed regarding age, renal function, ejection fraction, CHA~2~DS~2~-VASc score, AF as main admission diagnosis or ACS at admission.

Third, the present study addresses the role of hsTnT for stroke prediction in relation to established clinical risk factors and especially the guideline recommended CHA~2~DS~2~-VASc risk score in patients with AF. Our results confirm that the CHA~2~DS~2~-VASc risk score has a modest performance regarding stroke prediction with an AUC of 0.610 \[95% CI: 0.526--0.694\], compared to hsTnT with an AUC of 0.659 \[95% CI: 0.575--0.742\], the difference was not statistically significant (P = 0.250). Furthermore, elevated hsTnT was not only independently associated with stroke risk in patients with AF, but its inclusion to the multivariable model for stroke risk prediction consisting of all variables of the CHA~2~DS~2~-VASc score was associated with a significant improvement of its discriminatory power. By providing prognostic information independent of other clinical variables, hsTnT may be beneficial for stroke risk assessment in patients with AF. Further studies should evaluate hsTnT as a variable in risk scores for stroke risk prediction.

There are some limitations to the present study. Since only hsTnT was evaluated, conclusions on the role of conventional cardiac troponin T, conventional cardiac troponin I or high-sensitivity cardiac troponin I assays are not possible. The reported events were adjudicated by a single physician with the possible consequence of an observer bias. Bias from potentially missed events in patients without follow-up for stroke cannot be excluded. This is due to the fact that municipal registration offices had to be contacted in some cases, where only a follow-up for mortality could be obtained.

Conclusions {#sec014}
===========

The present study shows that elevated hsTnT is independently associated with higher rates of stroke in patients presenting to an emergency department with AF. Furthermore, hsTnT provides prognostic information independent of CHA~2~DS~2~-VASc risk score variables. In the light of these findings, hsTnT could serve as a valuable prognostic biomarker and its measurement should be considered for stroke risk prediction as compared to only using clinical variables. Further studies are warranted to evaluate the value of cardiac biomarkers as part of combined risk-scores or algorithms for stroke risk prediction, incorporating both clinical and biochemical variables.

Supporting information {#sec015}
======================

###### Kaplan-Meier curve for stroke in patients with atrial fibrillation, subgroup of patients with CHA~2~DS~2~-VASc score ≤ 2 (female) and CHA2DS2-VASc score ≤ 1 (male): hsTnT at or below the 99th percentile (hsTnT ≤ 14 ng/L, blue), and elevated hsTnT (hsTnT \> 14 ng/L, red).

hsTnT = high-sensitivity troponin T.
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Click here for additional data file.
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